Solving a sticky fibrotic problem

Temple Therapeutics BV’s first-in-class phase-3-ready drug candidate for postoperative fibrosis is ready for partnering for an untapped $5 billion market.

Go to the profile of Temple Therapeutics
Feb 28, 2017
1
0
Page of
Go to the profile of Temple Therapeutics

Temple Therapeutics

Awaken the body’s Power™ to protect, restore & regenerate Our vision is to “Challenge, Collaborate, Create” to bring innovative, impactful therapies which simplify and increase quality of life. Temple Therapeutics BV is a Dutch domiciled privately held company. We are a clinical stage company focused on developing products that are destined to address unmet medical needs in the hospital’s acute care and surgery departments. Temple’s development focus is on modifying disease. We believe in developing products that unlock the body’s intrinsic capacity to restore balance. Hence, your body is your Temple. Our goal is to develop treatments that truly increase quality of life and ease the financial burden. Our lead asset, Evitar™ has just completed phase I/II trial and is open to partnership opportunities as we enter the pivotal phase across USA, EU and Japan, including other regional markets. FDA meeting completed, regulatory and clinical pathways determined. Currently we are at the beginning stages of our fundraising campaign to complete additional studies including pivotal by 2018.

No comments yet.